shall be established in the Community. 2. In order to obtain traditional use registration, the applicant shall submit an application to the competent authority of the Member State concerned. Article 16c 1. The application shall be accompanied by: a) the following information: i) the particulars and documents referred to in Article 8(3) points (a) to (h), (j) and (k), ii) the results of pharmaceutical tests referred to in the first indent of Article 8(3) point (i), iii) the summary of product characteristics without the data specified in Article 11(4), iv) in case of a combination as referred to in Article 1 point 30, the information referred to in Article 16a point (e) relating to the combination as such; if the individual active ingredients are not sufficiently known, the data also need to relate to the individual active ingredients; b) any authorisation or registration obtained by the applicant in another Member State, or in a third country, to place the medicinal product on the market, and details of any decision to refuse to grant an authorisation or registration, whether in the Community or a third country, and the reasons for such a decision; c) bibliographical or expert evidence to the effect that the herbal substances, herbal preparations or their active ingredients at a pharmacological level in the medicinal product in question, or a corresponding medicinal product , have been in medicinal use in the Community over a period of at least thirty years preceding the date of application; d) a bibliographic review of safety data together with an expert report on the pharmacological and toxicological properties as well as on the possible therapeutic utility , and, where required by the competent authority, upon justified request, data necessary for assessing the safety of the medicinal product. Annex I shall apply by analogy to the particulars and documents specified in point (a). 2. A corresponding medicinal product, as referred to in paragraph 1, point (c), is characterised by having the same active ingredients, irrespective of the excipients used, the same or similar intended purpose, equivalent strength and the same or similar route of administration as the medicinal product applied for. 3. The requirement to show medicinal use throughout the period of thirty years referred to in paragraph 1 , point (c), is satisfied even where the marketing of the herbal substances, herbal preparations or their active ingredients at a pharmacological level in the